Figure 3 Low-grade inflammation in FGID

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 2 Endoscopic imaging of intestinal villi

Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 4 Activation of clopidogrel via cytochrome P450

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 The T-cell cytokine tree in IBD

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 3 Histological subtypes of intrahepatic CCA

Figure 3 The 'leaky gut' hypothesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

(A) Colonic mucosa with inflammation and necrosis (× 40) and (B) at higher magnification (× 100). (A) Colonic mucosa with inflammation and necrosis (×

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Example wireless motility recording

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Pseudorelaxation as a consequence of

Figure 1 Environmental factors contributing to IBD pathogenesis

Figure 1 Tropical sprue and PI-IBS

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Key brain–immune–gut interactions

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 High-resolution manometry studies performed

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Figure 3 Optical coherence tomography images of specialized intestinal

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 1 Mucosal immune networks

Figure 4 Local species pools that contribute to the

Figure 1 Endoscopic appearance of fundic gland polyps

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Phosphorylation of TRIO Y2681 in human colorectal cancer (CRC) is correlated with poorer prognosis. Phosphorylation of TRIO Y2681 in human colorectal cancer.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 8 Assessment of colonic tone using a barostat device

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence.

Figure 3 Endomicroscopy for optical intestinal biopsy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 3 Low-grade inflammation in FGID Figure 3 | Low-grade inflammation in FGID. a | Increased numbers of tryptase-positive mast cells (brown staining) in the colon of patients with IBS. b | Expansion of duodenal eosinophils in the duodenal mucosa of patient with functional dyspepsia. c | Eosinophil degranulation in duodenal mucosa of a patient with functional dyspepsia (carbol chromotrope stain, arrow) adjacent to nerves (S100 immunostaining, arrowhead). Inset: intact eosinophil. Magnification for parts a and b ×20, for part c ×40 and inset ×100. FGID, functional gastrointestinal disorder. Powell, N. et al. (2017) The mucosal immune system: master regulator of bidirectional gut–brain communications Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.191